We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coherus Offers Positive Phase III Data on Humira Biosimilar
Read MoreHide Full Article
Coherus BioSciences, Inc. (CHRS - Free Report) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.’s (ABBV - Free Report) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.
Coherus share price has surged 91.9% in the past one year, while the Zacks classified Medical-Biomedical and Genetics industry’s dipped 10.4%.
The confirmatory, randomized, double-blind, active-control, parallel-group study was conducted in patients with active, moderate-to-severe, chronic plaque psoriasis. As previously reported, the biosimilar candidate achieved the primary endpoint that showed similarity between CHS-1420 and Humira with respect to percentage of patients achieving 75% improvement in psoriasis area and severity index (PASI-75) at week 12.
Meanwhile, data from part 2 of the study focused on maintenance of response through week 24. In part 2 (weeks 16–24), maintenance of PASI-75 was found to be similar across the three subsequent treatment groups – CHS-1420 followed by CHS-1420, Humira followed by CHS-1420, and Humira followed by Humira. CHS-1420 and HUMIRA were also observed to be similarly well tolerated across all groups during part 2. All the patients will receive CHS-1420 for an additional 24 weeks in the part 3.
Coherus plans to present the data from the study at the forthcoming scientific conference. The company expects to submit biologic license application in the first half of 2017.
We remind investors that last year Amgen Inc. (AMGN - Free Report) received the FDA approval for its biosimilar version of Humira under the trade name Amjevita.
Zacks Rank & A Key Pick
Coherus currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Sucampo Pharmaceuticals, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016, however inched up from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 "Strong Sells" and other private research. See the stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Coherus Offers Positive Phase III Data on Humira Biosimilar
Coherus BioSciences, Inc. (CHRS - Free Report) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.’s (ABBV - Free Report) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.
Coherus share price has surged 91.9% in the past one year, while the Zacks classified Medical-Biomedical and Genetics industry’s dipped 10.4%.
The confirmatory, randomized, double-blind, active-control, parallel-group study was conducted in patients with active, moderate-to-severe, chronic plaque psoriasis. As previously reported, the biosimilar candidate achieved the primary endpoint that showed similarity between CHS-1420 and Humira with respect to percentage of patients achieving 75% improvement in psoriasis area and severity index (PASI-75) at week 12.
Meanwhile, data from part 2 of the study focused on maintenance of response through week 24. In part 2 (weeks 16–24), maintenance of PASI-75 was found to be similar across the three subsequent treatment groups – CHS-1420 followed by CHS-1420, Humira followed by CHS-1420, and Humira followed by Humira. CHS-1420 and HUMIRA were also observed to be similarly well tolerated across all groups during part 2. All the patients will receive CHS-1420 for an additional 24 weeks in the part 3.
Coherus plans to present the data from the study at the forthcoming scientific conference. The company expects to submit biologic license application in the first half of 2017.
We remind investors that last year Amgen Inc. (AMGN - Free Report) received the FDA approval for its biosimilar version of Humira under the trade name Amjevita.
Zacks Rank & A Key Pick
Coherus currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Sucampo Pharmaceuticals, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016, however inched up from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
Coherus BioSciences, Inc. Price
Coherus BioSciences, Inc. Price | Coherus BioSciences, Inc. Quote
Where Do Zacks' Investment Ideas Come From?
You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 "Strong Sells" and other private research. See the stocks free >>